Shirzad-Yazdi Nasrin, Namdari Nasrin, Noorani Anahid, Karimzadeh Iman
Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran.
Department of Clinical Pharmacy, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran.
J Res Pharm Pract. 2024 Sep 26;13(1):27-32. doi: 10.4103/jrpp.jrpp_21_24. eCollection 2024 Jan-Mar.
Due to the high morbidity and mortality of the coronavirus disease 2019 (COVID-19) in patients with malignancy, the necessity of vaccination in this group of patients became particularly important. Although a large number of studies have reported the safety of COVID-19 vaccination in multiple myeloma (MM) patients, the effect of the COVID-19 vaccine on MM relapse has not yet been reported. Here, we report a case of a possible association between relapse of MM and COVID-19 vaccination with Sinopharm, an inactivated virus vaccine, in a patient with MM who has remained in complete remission for about 4 years. The MM relapse in the patient was diagnosed by both clinical findings and laboratory workup including serum protein electrophoresis, bone marrow aspiration, and biopsy. Despite this possible association between COVID-19 vaccination and MM relapse in the patient, given its importance in reducing mortality and having an acceptable safety profile, the COVID-19 vaccine should be administered to all cancer patients. However, careful monitoring and follow-up are recommended in patients with MM after COVID-19 vaccination.
由于2019冠状病毒病(COVID-19)在恶性肿瘤患者中的高发病率和死亡率,这组患者接种疫苗的必要性变得尤为重要。尽管大量研究报告了COVID-19疫苗在多发性骨髓瘤(MM)患者中的安全性,但COVID-19疫苗对MM复发的影响尚未见报道。在此,我们报告1例MM患者在完全缓解约4年后接种国药集团的灭活病毒疫苗COVID-19后MM复发的可能关联病例。该患者的MM复发通过临床症状及包括血清蛋白电泳、骨髓穿刺和活检在内的实验室检查确诊。尽管该患者中COVID-19疫苗接种与MM复发之间存在这种可能的关联,但鉴于其在降低死亡率方面的重要性以及具有可接受的安全性,COVID-19疫苗仍应接种于所有癌症患者。然而,建议MM患者在接种COVID-19疫苗后进行密切监测和随访。